Celgene

This early-stage study tested a combination of two drugs, alnuctamab and mezigdomide, in people with multiple myeloma that had come back or stopped responding to treatment. The goal was to find the right dose and check safety. Only 4 people took part before the study was stopped …

This study tested whether the oral drug ozanimod could help people with moderate to severe Crohn's disease maintain improvement over a year. About 550 adults who had already responded to an initial treatment were randomly assigned to receive ozanimod or a placebo. The trial was t…

This study tested an oral medication called ozanimod to help people with moderate-to-severe Crohn's disease reach remission (fewer symptoms). About 625 adults with Crohn's who had not responded well to other treatments were randomly assigned to receive ozanimod or a placebo for 1…

This study tested a cell therapy called bb2121 (Ide-cel) combined with other drugs in adults with multiple myeloma that had returned or stopped responding to treatment. The goal was to find the best dose and check safety and effectiveness. The study was terminated early after enr…

This study tested a new drug called CC-92480, alone or with dexamethasone, in people with multiple myeloma that returned or didn't respond to at least three prior treatments. The goal was to check safety, find the right dose, and see if it could shrink tumors. The trial was stopp…

This study looked at the long-term safety and effectiveness of the oral drug ozanimod for people with moderate to severe Crohn's disease. It was an extension study for participants who completed earlier studies. The study was terminated early, so results are limited.

This study was a registry that followed over 3,000 adults newly diagnosed with multiple myeloma to understand how the disease is managed in everyday medical practice. Researchers collected information on patient backgrounds, treatments, and outcomes without providing any new ther…